Daraxonrasib should be used with caution in specific populations. The following introduces medication guidance for patients with severe hepatic o...
Daraxonrasib is an inhibitor of the RAS GTPase family, indicated for the treatment of adult patients with metastatic pancreatic adenocarcinoma wh...
Canaglu(canagliflozin)belongs to SGLT2 inhibitors,and its action depends on the renal glucose excretion mechanism.Therefore,it is contraindicated...
Canagliflozin lowers blood glucose through urinary glucose excretion.During medication,close attention should be paid to three types of risks:gen...
Canagliflozin lowers blood glucose by promoting urinary glucose excretion, but it may cause adverse reactions such as urinary tract infections, t...
Canaglu (canagliflozin) is an SGLT2 inhibitor antidiabetic drug, usually taken once daily. The timing is flexible, but missed dose management and...
Acneiform rash, paronychia, and diarrhea often occur during afatinib treatment. Standardized management can relieve discomfort and help patients ...
Afatinib is used for the treatment of certain non-small cell lung cancers, but some populations should avoid it or use it with caution. The follo...
Common adverse reactions of afatinib include diarrhea, rash, stomatitis, and hepatotoxicity. Timely identification and management are key to ensu...
Afatinib is an oral tyrosine kinase inhibitor used to treat certain types of non-small cell lung cancer. The following briefly introduces its dos...